Physician profile
Lawrence D Davanzo
NPI 1902834708
$25,963.76
in general payments reported to CMS, 2019-2025
42 companies · $5,858 in 2025
The $5,858 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,350 · 2020: $2,603 · 2021: $2,752 · 2022: $3,322 · 2023: $4,333 · 2024: $4,746 · 2025: $5,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,355.83 |
| Education | $581.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $6,590.70 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $4,997.37 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Jazz Pharmaceuticals INC. | $2,072.71 | 2019-2025 | Xywav |
| Actelion Pharmaceuticals US, INC. | $1,723.58 | 2019-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,674.23 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Genzyme Corporation | $1,012.56 | 2019-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $945.14 | 2023-2025 | Lumryz |
| Harmony Biosciences LLC | $918.57 | 2020-2025 | Wakix |
| Mylan Specialty L.P. | $845.43 | 2019-2024 | Yupelri |
| Axsome Therapeutics, INC. | $712.08 | 2022-2025 | Sunosi |
| Amgen INC. | $533.15 | 2021-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $350.30 | 2019-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $346.43 | 2019-2025 | Winrevair, Belsomra, Recarbrio |
| Mallinckrodt Hospital Products INC. | $327.31 | 2020-2025 | Acthar |
| Grifols USA, LLC | $318.34 | 2019-2025 | Prolastin-C Liquid |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $245.38 | 2019-2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $242.25 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Bayer Healthcare Pharmaceuticals INC. | $238.61 | 2019-2025 | |
| Genentech USA, INC. | $198.45 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $194.94 | 2023-2024 | |
| Inspire Medical Systems, INC. | $192.34 | 2023-2025 | Inspire |
| Philips North America LLC | $163.46 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $134.07 | 2020-2024 | Aralast |
| Electromed, INC. | $124.93 | 2019-2025 | Smartvest |
| Vanda Pharmaceuticals INC. | $115.03 | 2021-2023 | Hetlioz |
| Novartis Pharmaceuticals Corporation | $88.22 | 2019-2021 | |
| Gilead Sciences, INC. | $79.46 | 2019-2021 | |
| Circassia INC. | $70.48 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $67.69 | 2021 | |
| Baxter Healthcare | $67.52 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Verona Pharma, INC. | $53.89 | 2025 | Ohtuvayre |
| Inogen, INC. | $51.97 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Azurity Pharmaceuticals, INC. | $51.31 | 2024 | Horizant |
| Pulmonx Corporation | $47.52 | 2022-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Idorsia Pharmaceuticals US INC | $29.25 | 2023 | Quviviq |
| Paratek Pharmaceuticals, INC. | $28.39 | 2022 | |
| Mallinckrodt Enterprises LLC | $25.52 | 2019 | |
| Itamar Medical INC | $22.37 | 2023 | Watchpatone |
| Viatris Specialty LLC | $19.92 | 2025 | Yupelri |
| Resmed Corp | $15.10 | 2020 | |
| Shire North American Group INC | $14.54 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Davanzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.